Full-Time
Alliance Manager
Posted on 5/10/2025
Synthego
51-200 employees
Provides synthetic RNA and gene editing tools
Compensation Overview
$105k - $125k/yr
Mid
San Carlos, CA, USA
This is a remote position, but candidates must be based in the US.
- Bachelor’s degree in biological sciences, biochemistry, chemistry, chemical engineering or related field
- Minimum 2+ years of experience in project management, technical/customer service, or program management in a biotechnology, within CDMO, or related field
- Proven track record of managing projects from initiation through to completion, ensuring timely status updates and milestone communication throughout
- Excellent organizational, relationship and communication skills
- Motivation to be part of a fast-paced, multi-disciplinary team
- Excellent problem-solving skills
- Able to multi-task and prioritize work effectively
- Independently manage client projects from order initiation through execution and post-project documentation
- Provide timely updates on project status and proactively manage key milestones to ensure successful outcomes
- Establish and maintain strong client relationships through regular communication and responsive support
- Partner with the Sales team to support client discussions during the late stages of the sales cycle
- Partner with Product Management to provide input on timelines, technical considerations, and deliverables to shape the final proposal and Statement of Work (SOW)
- In conjunction with internal stakeholders, help solidify project initiation plans by supporting final review discussions and ensuring readiness for kickoff once contracts are signed
- Organize and lead internal and external meetings, including project kick-offs, status reviews, and close-outs
- Ensure all action items are documented and followed through to completion
- Conduct regular video calls and written updates to share manufacturing timelines, highlight risks, and address quality concerns with anticipated resolution timelines
- Hold daily touchpoints with Operations and Quality teams to ensure alignment on project status
- Collaborate closely with Manufacturing, Quality Systems, and Supply Chain to ensure timely and accurate product delivery
- Pull in internal subject matter experts to support technical discussions, particularly around deviations and non-conformances
- Act as a client advocate, identifying and resolving issues with urgency and transparency
- Navigate complex cross-functional asks, such as coordinating global client requirements (e.g., CCIT studies), by aligning teams across Product, Operations, Supply Chain, and QA
- Contribute to the development and implementation of project management best practices and tools
- With the support of the Manager, define and monitor KPIs related to project delivery, client satisfaction, and internal efficiency
- Champion a culture of accountability, transparency, and continuous improvement
- Project management or client relationship management experience within a contract development and manufacturing organization (CDMO)
- Drug development knowledge with strong understanding of research, preclinical, clinical, manufacturing, commercial and regulatory areas
Synthego specializes in biotechnology, focusing on genetic engineering by providing synthetic RNA and gene editing tools. Their products enable scientists to modify genes, which can lead to advancements in disease treatment and agricultural improvements. Synthego serves a variety of clients, including research institutions, pharmaceutical companies, and biotech startups, who utilize their tools for drug discovery, disease modeling, and genetic research. The company stands out in the growing genetic engineering market by offering a platform that grants users access to advanced gene editing capabilities, alongside their synthetic RNA products. Synthego's goal is to support and enhance genetic research and applications through their essential tools and services.
Company Size
51-200
Company Stage
Series E
Total Funding
$459.7M
Headquarters
Menlo Park, California
Founded
2012
Simplify's Take
What believers are saying
- Synthego's licensing agreements expand access to advanced CRISPR tools for therapeutic applications.
- The launch of IND-enabling gRNAs supports the entire CRISPR-based therapeutic development pipeline.
- Opening a new research lab in Redwood City boosts production and innovation in genome engineering.
What critics are saying
- Intellectual property disputes may arise from Synthego's licensing agreements.
- Rapid technological advancements could render Synthego's current offerings obsolete.
- Reliance on strategic partnerships poses risks if these collaborations dissolve.
What makes Synthego unique
- Synthego integrates machine learning and automation in its genome engineering platform.
- The company offers high-fidelity CRISPR systems like hfCas12Max for precise gene editing.
- Synthego's partnerships with AstraZeneca and bit.bio enhance its therapeutic development capabilities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Generous Equity Package
Medical, Dental & Vision
401(k) Plan
Catered to You
Fully Stocked
Transportation
Green Environment
Stay Fit
Legal Ease
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↓ -3%Synthego introduced the hfCas12Max CRISPR system in 2024, the first in its portfolio of high-fidelity nucleases designed specifically for therapeutic applications.
REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic programs. This nonexclusive sublicense grants Vita Therapeutics access to the engineered hfCas12Max nuclease and optimized hfCas12Max guide RNAs for use in preclinical and clinical applications, including in potential commercialized therapeutics. "With the integration of hfCas12Max, Vita Therapeutics can accelerate the development of their hypoimmunogenic cell therapies, paving the way for life-changing treatments to reach patients sooner," said Craig Christianson, CEO of Synthego. "Our goal is to make therapeutic CRISPR solutions more accessible by removing traditional bottlenecks with reduced upfront licensing fees and a lower total IP cost as the therapy advances."
REDWOOD CITY, Calif., Jan. 13, 2025 /PRNewswire/ -- Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9 , to the worldwide research community. This state-of-the-art nuclease, developed by AstraZeneca, will be paired with Synthego's best-in-class gRNA to enable improved health outcomes.Under the terms of the agreement, Synthego also receives exclusive commercialization rights including the right to sublicense this nuclease for therapeutic and commercial use."Our agreement with AstraZeneca is a testament to our commitment to guiding researchers with customized CRISPR solutions that empower their therapeutic pursuits," said Craig Christianson, CEO of Synthego. "By enhancing our CRISPR expertise with AstraZeneca's novel nuclease, we are poised to expedite the development of transformative therapies, paving a streamlined and accelerated path to clinical advancement."Synthego's innovative approach simplifies the licensing process for CRISPR cell and gene therapies, ensuring that novel and groundbreaking nucleases and gRNAs are within reach for researchers. The company's extensive regulatory and technical expertise further bolsters the therapeutic development pipeline, providing a seamless integration from concept to clinic."We are excited to offer significantly lower upfront fees for rights to a leading CRISPR enzyme enabling therapeutic developers to de-risk their fundraising process, and making overall development costs significantly less than with traditional nucleases," continued Christianson.This licensing agreement marks a significant milestone in the field of CRISPR therapeutics, combining the strengths of Synthego's advanced solutions with AstraZeneca's innovative gene therapy technology
SHANGHAI and REDWOOD CITY, Calif. , May 29, 2024 /PRNewswire/ -- HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company focused on advancing CRISPR-based genomic medicines, and Synthego Corporation ("Synthego"), a leading provider of innovative CRISPR solutions for developing cell and gene therapies, proudly announce a partnered licensing agreement for the high-fidelity Cas12 CRISPR nuclease (hfCas12Max). This partnership underscores the significant clinical utility of hfCas12Max, naturally complementing Synthego's focus on advanced GMP manufacturing capabilities. Under this licensing agreement and pursuant to undisclosed financial terms between HuidaGene and Synthego, HuidaGene grants Synthego manufacturing and commercialization rights for the hfCas12Max nuclease and optimized gRNA for research; HuidaGene also grants Synthego the right to sublicense the nuclease for therapeutic use.This partnership will streamline the development of CRISPR-based therapeutic applications, providing developers with access to highly precise, efficient, and next-generation genome editing tools. Xuan Yao, Ph.D., Co-founder and President of HuidaGene, emphasized the significance of this agreement, stating, "HuidaGene's expansive CRISPR intellectual property portfolio distinguishes it as a vanguard in genomic medicine, with a versatile pipeline targeting critical neurological and ophthalmological conditions. Together with Synthego, we are poised to significantly accelerate the advancement of CRISPR-based therapies and deliver life-altering genomic medicines to patients worldwide."Craig Christianson, CEO of Synthego, expressed enthusiasm about the partnership with HuidaGene on hfCas12Max, stating, "The combination of our advanced CRISPR GMP production capabilities and regulatory expertise with HuidaGene's next-generation nuclease technology is a crucial step toward advancing transformative cell and gene therapies
Synthego also announced the addition of Dr. Bill Skarnes, a pioneer in stem cell research, to the company's advisory board.